AMGEN INC (AMG.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:AMG - US0311621009 - Common Stock
AMG.DE Key Statistics, Chart & Performance
The current stock price of AMG.DE is 279.4 EUR. In the past month the price decreased by -5.11%. In the past year, price increased by 10.77%.
AMG.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.41 | 44.56B | ||
| 1AE.DE | ARGENX SE | 67.67 | 44.08B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.80B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.39B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.93B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.86B | ||
| NANO.PA | NANOBIOTIX | N/A | 918.99M | ||
| 5CV.DE | CUREVAC NV | 6.24 | 815.12M | ||
| IVA.PA | INVENTIVA SA | N/A | 770.76M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M | ||
| FYB.DE | FORMYCON AG | N/A | 455.89M |
Related stock screener links
About AMG.DE
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 28000
Phone: 18054471000
AMGEN INC / AMG.DE FAQ
What does AMGEN INC do?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Can you provide the latest stock price for AMGEN INC?
The current stock price of AMG.DE is 279.4 EUR. The price decreased by -0.32% in the last trading session.
What is the dividend status of AMGEN INC?
AMGEN INC (AMG.DE) has a dividend yield of 3.02%. The yearly dividend amount is currently 7.65.
How is the ChartMill rating for AMGEN INC?
AMG.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for AMG stock?
The PE ratio for AMGEN INC (AMG.DE) is 15.01. This is based on the reported non-GAAP earnings per share of 18.61 and the current share price of 279.4 EUR.
Can you provide the growth outlook for AMGEN INC?
The Revenue of AMGEN INC (AMG.DE) is expected to grow by 9.43% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of AMG stock?
AMGEN INC (AMG.DE) has a market capitalization of 150.45B EUR. This makes AMG.DE a Large Cap stock.
AMG.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AMG.DE. When comparing the yearly performance of all stocks, AMG.DE is one of the better performing stocks in the market, outperforming 74.6% of all stocks.
AMG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMG.DE. AMG.DE has an excellent profitability rating, but there are concerns on its financial health.
AMG.DE Financial Highlights
Over the last trailing twelve months AMG.DE reported a non-GAAP Earnings per Share(EPS) of 18.61. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.47% | ||
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| Debt/Equity | 5.45 |
AMG.DE Forecast & Estimates
41 analysts have analysed AMG.DE and the average price target is 288.02 EUR. This implies a price increase of 3.09% is expected in the next year compared to the current price of 279.4.
For the next year, analysts expect an EPS growth of 9.46% and a revenue growth 9.43% for AMG.DE